MXPA05005073A - Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. - Google Patents

Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.

Info

Publication number
MXPA05005073A
MXPA05005073A MXPA05005073A MXPA05005073A MXPA05005073A MX PA05005073 A MXPA05005073 A MX PA05005073A MX PA05005073 A MXPA05005073 A MX PA05005073A MX PA05005073 A MXPA05005073 A MX PA05005073A MX PA05005073 A MXPA05005073 A MX PA05005073A
Authority
MX
Mexico
Prior art keywords
sepsis
diagnosis
onset
individual
severe
Prior art date
Application number
MXPA05005073A
Other languages
English (en)
Inventor
Tice Gregory
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of MXPA05005073A publication Critical patent/MXPA05005073A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La prediccion o diagnostico temprano de sepsis es una ventaja para la intervencion clinica antes de que la enfermedad progrese con rapidez mas alla de las etapas iniciales a las etapas mas graves, como pueden ser sepsis o shock septico grave, que estan asociadas con elevada mortalidad. La prediccion o diagnostico temprano se logra comparando el perfil de un individuo de la expresion de un biomarcador con los perfiles que se obtienen de una o mas poblaciones testigo o de referencia, las cuales pueden incluir una poblacion que desarrolle sepsis. El reconocimiento de las caracteristicas en le perfil del biomarcador del individuo que son caracteristicas del inicio de sepsis permite a un clinico diagnosticar el comienzo de sepsis a partir de un fluido corporal tomado del individuo en un solo punto en el tiempo. La necesidad de supervisar al paciente durante un lapso de tiempo, por tanto, se evita ventajosamente permitiendo la intervencion clinica antes de que se inicien los sintomas graves de sepsis.
MXPA05005073A 2002-11-12 2003-11-12 Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. MXPA05005073A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42532202P 2002-11-12 2002-11-12
US51164403P 2003-10-17 2003-10-17
PCT/US2003/036019 WO2004044554A2 (en) 2002-11-12 2003-11-12 Diagnosis of sepsis or sirs using biomarker profiles

Publications (1)

Publication Number Publication Date
MXPA05005073A true MXPA05005073A (es) 2005-11-17

Family

ID=32314585

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005073A MXPA05005073A (es) 2002-11-12 2003-11-12 Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.

Country Status (9)

Country Link
US (2) US20040096917A1 (es)
EP (1) EP1573054A4 (es)
JP (1) JP2006515670A (es)
AU (1) AU2003291482A1 (es)
BR (1) BR0316231A (es)
CA (1) CA2505902A1 (es)
MX (1) MXPA05005073A (es)
TW (1) TW200418992A (es)
WO (1) WO2004044554A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
CA2457432A1 (en) * 2001-08-13 2003-02-27 Jan Van Der Greef Method and system for profiling biological systems
US20040157242A1 (en) * 2002-11-12 2004-08-12 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
JP2006506069A (ja) * 2002-11-12 2006-02-23 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロフィールを用いた敗血症またはｓｉｒｓの診断
US20060177870A1 (en) * 2003-04-28 2006-08-10 Ciphergen Biosystems, Inc Immunoassays
AU2004267806A1 (en) * 2003-08-20 2005-03-03 Bg Medicine, Inc. Methods and systems for profiling biological systems
WO2005048823A2 (en) * 2003-11-17 2005-06-02 Janssen Pharmaceutica N.V. Modeling of systemic inflammatory response to infection
EP1718763B1 (en) * 2003-12-05 2011-09-21 McGill University Serum biomarkers for chagas disease
US20050181398A1 (en) * 2004-01-16 2005-08-18 Fung Eric T. Specific detection of host response protein clusters
DE102004009952B4 (de) * 2004-03-01 2011-06-01 Sirs-Lab Gmbh Verfahren zur Erkennung von Sepsis
DE102004015605B4 (de) * 2004-03-30 2012-04-26 Sirs-Lab Gmbh Verfahren zur Vorhersage des individuellen Krankheitsverlaufs bei Sepsis
DE102004049897B4 (de) * 2004-10-13 2007-11-22 Sirs-Lab Gmbh Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
PT1815247E (pt) * 2004-11-05 2013-04-23 Janssen Pharmaceutica Nv Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
GB0426982D0 (en) * 2004-12-09 2005-01-12 Secr Defence Early detection of sepsis
DE102005013013A1 (de) * 2005-03-21 2006-09-28 Sirs-Lab Gmbh Verwendung von Genaktivitäts-Klassifikatoren für die in vitro Klassifizierung von Genexpressionsprofilen von Patienten mit infektiösem/nichtinfektiösem Multiorganversagen
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
US20090136966A1 (en) * 2005-07-28 2009-05-28 Biosystems International Sas Normalization of Complex Analyte Mixtures
DE102005042133A1 (de) * 2005-09-05 2007-03-08 Sirs-Lab Gmbh Verfahren zur Diagnose von Sepsis mit Apolipoprotein A1
US20080254496A1 (en) * 2005-09-27 2008-10-16 Shuster Jeffrey R Methods for Detection of Fungal Disease
BRPI0616720A2 (pt) 2005-09-28 2011-06-28 Becton Dickinson Co método para o diagnóstico ou prognóstico de sepse em um paciente, kit para diagnóstico ou prognóstico, ou monitoração, de sepse em um paciente, e, dispositivo para o diagnóstico ou prognóstico de sepse
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
ATE472611T1 (de) * 2005-11-25 2010-07-15 Trinity College Dublin Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
EP1963527A2 (en) * 2005-12-15 2008-09-03 Becton, Dickinson and Company, Wagner, Jaconda Diagnosis of sepsis
GB0610078D0 (en) * 2006-05-20 2006-06-28 Secr Defence Sepsis detection microarray
US8084734B2 (en) * 2006-05-26 2011-12-27 The George Washington University Laser desorption ionization and peptide sequencing on laser induced silicon microcolumn arrays
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
JP5357871B2 (ja) * 2007-07-13 2013-12-04 コーニンクレッカ フィリップス エヌ ヴェ 急性の動的な疾患の意思決定支援システム
US8901487B2 (en) 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
GB0722582D0 (en) * 2007-11-16 2007-12-27 Secr Defence Early detection of sepsis
ES2524669T3 (es) * 2007-11-16 2014-12-10 Biocartis Nv Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
US7776522B2 (en) * 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
AU2009244200B2 (en) 2008-05-07 2012-10-18 Lawrence A. Lynn Medical failure pattern search engine
KR100976218B1 (ko) * 2008-05-26 2010-08-17 한국표준과학연구원 비행시간이차이온질량분광법을 이용한 질병의 진단 방법,질병 지표의 스크린 방법, 및 질병 지표
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US8110796B2 (en) 2009-01-17 2012-02-07 The George Washington University Nanophotonic production, modulation and switching of ions by silicon microcolumn arrays
US9490113B2 (en) * 2009-04-07 2016-11-08 The George Washington University Tailored nanopost arrays (NAPA) for laser desorption ionization in mass spectrometry
EP2308999A1 (en) * 2009-09-24 2011-04-13 Ludwig-Maximilians-Universität München A combination of markers for predicting the mortality risk in a polytraumatized patient
WO2011082433A1 (en) * 2010-01-04 2011-07-07 Lineagen, Inc. Metabolomics-based biomarkers for lung function
JP2014524121A (ja) 2011-07-14 2014-09-18 ザ・ジョージ・ワシントン・ユニバーシティ レーザアブレーション・エレクトロスプレイイオン化質量分析用のプルームコリメーション
EP2575065A1 (en) * 2011-09-30 2013-04-03 General Electric Company Remote health monitoring system
US9953453B2 (en) 2012-11-14 2018-04-24 Lawrence A. Lynn System for converting biologic particle density data into dynamic images
US10354429B2 (en) 2012-11-14 2019-07-16 Lawrence A. Lynn Patient storm tracker and visualization processor
WO2014134522A1 (en) 2013-02-28 2014-09-04 Lynn Lawrence A System and method for generating quaternary images of biologic force propagation and recovery
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
SG11201510282PA (en) * 2013-06-28 2016-01-28 Acumen Res Lab Pte Ltd Sepsis biomarkers and uses thereof
CA2931614A1 (en) 2013-11-25 2015-05-28 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
AU2015213486B2 (en) 2014-02-06 2020-10-22 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis
CA2942577A1 (en) * 2014-03-14 2015-09-17 Robert E. W. Hancock Diagnostic for sepsis
ES2840056T3 (es) * 2016-11-04 2021-07-06 Centro De Investig Biomedica En Red Ciber Isciii Métodos basados en espectrometría de masas para la detección de histonas circulantes H3 y H2B en plasma a partir de pacientes con septicemia o choque séptico (SS)
CN106778064A (zh) * 2016-12-20 2017-05-31 上海派森诺生物科技股份有限公司 无参转录组自动化分析方法
DE102017008885B4 (de) * 2017-09-22 2024-04-25 Bruker Daltonics GmbH & Co. KG Massenspektrometrisches Verfahren und MALDI-TOF-Massenspektrometer
GB2568354B (en) * 2017-09-28 2022-08-10 Bruker Daltonics Gmbh & Co Kg Wide-range high mass resolution in reflector time-of-flight mass spectrometers
CN109374904A (zh) * 2018-10-29 2019-02-22 浙江医院 一种蛋白质类脓毒症标志物及其在严重脓毒症早期预警的应用及其筛选方法
KR20230015938A (ko) 2020-05-25 2023-01-31 팜-아날리트 레이버 게엠베하 패혈증 증상 예측
WO2023019093A2 (en) * 2021-08-07 2023-02-16 Venn Biosciences Corporation Detection of peptide structures for diagnosing and treating sepsis and covid

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506195A (ja) * 1991-01-14 1994-07-14 ニューヨーク　ユニバシテイ サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5389522A (en) * 1993-03-19 1995-02-14 Repine; John E. Serum antioxidants as predictors of the adult respiratory distress syndrome in septic patients
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US6190872B1 (en) * 1994-05-06 2001-02-20 Gus J. Slotman Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method
US5804370A (en) * 1994-06-08 1998-09-08 Critichem Medical Products Limited Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
US5932536A (en) * 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5780237A (en) * 1994-10-12 1998-07-14 Cell Therapeutics, Inc. Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6429017B1 (en) * 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US5981180A (en) * 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US5830679A (en) * 1996-03-01 1998-11-03 New England Medical Center Hospitals, Inc. Diagnostic blood test to identify infants at risk for sepsis
US6077665A (en) * 1996-05-07 2000-06-20 The Board Of Trustees Of The Leland Stanford Junior University Rapid assay for infection in neonates
US6172220B1 (en) * 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
US6420526B1 (en) * 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
EP0881494A1 (de) * 1997-04-29 1998-12-02 Roche Diagnostics GmbH Verfahren zur simultanen Bestimmung von Proteinen bzw. entsprechenden Derivaten
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
JP4357112B2 (ja) * 1997-10-14 2009-11-04 ルミネックス コーポレイション 精密蛍光染色された粒子及びその製造及び使用方法
US6159683A (en) * 1997-12-16 2000-12-12 Spectral Diagnostics, Inc. Method of determining stage of sepsis
JP3468750B2 (ja) * 1998-01-22 2003-11-17 ルミネックス コーポレイション 多数の蛍光シグナルを有する微小粒子
AU3897999A (en) * 1998-05-14 1999-11-29 Luminex Corporation Multi-analyte diagnostic system and computer implemented process for same
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
US6316197B1 (en) * 1999-02-05 2001-11-13 The United States Of America As Represented By The Secretary Of The Army Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20050060101A1 (en) * 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20040225449A1 (en) * 1999-06-28 2004-11-11 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using selected gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
DE10027113A1 (de) * 1999-12-23 2001-09-27 Andreas Hoeft Verfahren zur Bestimmung von mikrobieller DNS/RNS, Kit dafür und Verwendung des Verfahrens
US6660482B1 (en) * 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
US7363165B2 (en) * 2000-05-04 2008-04-22 The Board Of Trustees Of The Leland Stanford Junior University Significance analysis of microarrays
SG144731A1 (en) * 2000-07-18 2008-08-28 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
AU4153502A (en) * 2000-11-16 2002-06-03 Ciphergen Biosystems Inc Method for analyzing mass spectra
EP1360336A2 (en) * 2001-02-15 2003-11-12 Bayer Corporation Innate immunity markers for rapid diagnosis of infectious diseases
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040121350A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
EP1270740A1 (en) * 2001-06-29 2003-01-02 SIRS-Lab GmbH Biochip and its use for determining inflammation
CA2458667A1 (en) * 2001-08-30 2003-03-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Educat Ion Of Pennsylvania Method for predicting the outcome of an infection
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US20030057106A1 (en) * 2001-09-12 2003-03-27 Zhouxin Shen High throughput chemical analysis by improved desorption/ionization on silicon mass spectrometry
US6939716B2 (en) * 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
JP5236856B2 (ja) * 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
DE10155600B4 (de) * 2001-11-09 2009-08-27 Oligene Gmbh Nukleinsäure-Array
US20040072237A1 (en) * 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
US20040038201A1 (en) * 2002-01-22 2004-02-26 Whitehead Institute For Biomedical Research Diagnostic and therapeutic applications for biomarkers of infection
US7282368B2 (en) * 2002-02-27 2007-10-16 Biomerieux, Inc. Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
US7465555B2 (en) * 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
EP1369693A1 (de) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Sepsisdiagnose und zur Kontrolle von Spenderblut durch Bestimmung von anti-Asialo-Gangliosid-Antikörpern
NL1020962C2 (nl) * 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
US20040009503A1 (en) * 2002-07-03 2004-01-15 Molecular Staging, Inc. Immune modulatory activity of human ribonucleases
EP1521624A2 (en) * 2002-07-11 2005-04-13 Upfront Chromatography A/S An extracorporeal stabilised expanded bed adsorption method for the treatment of sepsis
EP2386863A1 (en) * 2002-10-09 2011-11-16 DMI Biosciences, Inc. Diagnosis and monitoring of multiple organ failure
US20040157242A1 (en) * 2002-11-12 2004-08-12 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
JP2006506069A (ja) * 2002-11-12 2006-02-23 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロフィールを用いた敗血症またはｓｉｒｓの診断
FR2855832B1 (fr) * 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US20050181386A1 (en) * 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
WO2005033327A2 (en) * 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1869463A4 (en) * 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS

Also Published As

Publication number Publication date
EP1573054A2 (en) 2005-09-14
AU2003291482A1 (en) 2004-06-03
CA2505902A1 (en) 2004-05-27
BR0316231A (pt) 2005-10-04
US20080138832A1 (en) 2008-06-12
TW200418992A (en) 2004-10-01
US20040096917A1 (en) 2004-05-20
EP1573054A4 (en) 2005-12-28
JP2006515670A (ja) 2006-06-01
WO2004044554A2 (en) 2004-05-27
WO2004044554A3 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
MXPA05005073A (es) Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
WO2004044555A3 (en) Diagnosis of sepsis or sirs using biomarker profiles
WO2004043236A3 (en) Diagnosis of sepsis or sirs using biomarker profiles
Tsunoda et al. Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients
WO2004112572A3 (en) Monitoring immunologic, hematologic and inflammatory diseases
WO2007007129A3 (en) Diagnostic method for brain damage-related disorders
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
HK1076702A1 (en) System and method for predicting the onset of cardiac pathology using fractal analysis
Perrin et al. Genetics of cardiac electrical disease
WO2021024198A3 (en) System and method for risk assessment of autism spectrum disorder
Orifovna et al. THE ROLE OF TRANSFORMING GROWTH FACTOR-β1 IN THE DEVELOPMENT OF PROCESSES OF FIBROSIS IN THE HEART AND KIDNEY IN PATIENTS WITH DIABETES WITH CHRONIC HEART FAILURE
BR0108802A (pt) Métodos de diagnóstico e terapêuticos para glaucoma
WO2002092858A3 (en) Methods of screening for disease
KR20160083502A (ko) 치주질환 예측 시스템 및 이를 이용한 치주질환 예측 방법
Abele et al. Spectral analysis of heart rate variability in multiple system atrophy and unexplained sporadic ataxia
Berezin et al. Decreased serum levels of irisin predicted heart failure in patients with type 2 diabetes mellitus
Gasperino et al. 1069: SEPSIS WITHOUT WALLS: A QUALITY IMPROVEMENT PROJECT
Shibata et al. Clinical Value of Troponin Levels to Cardiac Function and Prognosis in Patients with Fulminant Myocarditis
Lembo et al. P600 Impact of the use of left ventricular mass/end-diastolic volume ratio by 3D echocardiography on 2D derived global longitudinal strain and diastolic function in native hypertensive patients
Páll et al. P-298: Screening of adolescent hypertension, and evaluation of target organ damages. Results from the Debrecen hypertension study
Ruzhanska et al. Galectin-3 as a marker of myocardial function in men aged 40-60 years without cardiovascular pathology, carriers of polymorphic genes at1r
Abate et al. AGE TRENDS IN BLOOD PRESSURE DERLY.
Su et al. 1352 Relationship between urinary 8-iso-prostaglandin f2a and vulnerability of coronary culprit lesions in diabetic patients with acute coronary syndrome
Tharwet H et al. B-natriuretic peptide level as a predictor for the severity of LV dysfunction
Woudstra et al. SURVIVAL OF PATIENTS AFTER ST-ELEVATION MYOCARDIAL INFARCTION: EXTERNAL VALIDATION OF A PREDICTIVE BIOMARKER MODEL

Legal Events

Date Code Title Description
FA Abandonment or withdrawal